Congress 2014 has ended
Back To Schedule
Friday, May 2 • 11:45am - 12:45pm
Shedding Light on a Second-Line Advanced RCC Treatment: Importance of Adherence to Oral Medication

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Join your oncology nurse colleagues in attending this non-CNE promotional event sponsored by Pfizer Inc, spotlighting INLYTA® (axitinib) tablets as a treatment for patients with advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.

During this presentation, you will learn about the therapy, the indication, the product mechanism of action, clinical study results, and the benefits and risks of treatment. You will also learn about the importance of adherence to oral medication.

This is a Pfizer promotional activity. 

Seating is on a first-come, first-served basis. Please plan to arrive early to have the best chance at securing your seat. 


Julia A. Batten, APRN, MPH

Nurse Practitioner, Medical Oncology, Huntsman Cancer Institute

Friday May 2, 2014 11:45am - 12:45pm PDT
Theater 1, Hall B Anaheim Convention Center, 800 W. Katella Avenue. Anaheim, CA 92802
  Industry Event
  • CNE Status No CNE
  • Contact Hours of CNE: N/A

Attendees (0)